Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

BACKGROUND: Anlotinib showed significant survival benefits in advanced non‐small cell lung cancer (NSCLC) patients as a third‐ or further‐line treatment in the ALTER0303 trial. We aimed to evaluate the efficacy of anlotinib in patients with different histologies. METHODS: The ALTER0303 trial was a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Han, Baohui, Li, Kai, Wang, Qiming, Zhang, Li, Shi, Jianhua, Wang, Zhehai, He, Jianxing, Shi, Yuankai, Chen, Weiqiang, Wang, Xiuwen, Luo, Yi, Nan, Kejun, Jin, Faguang, Li, Baolan, Zhu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163095/
https://www.ncbi.nlm.nih.gov/pubmed/32064794
http://dx.doi.org/10.1002/cam4.2913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163095/
https://www.ncbi.nlm.nih.gov/pubmed/32064794
http://dx.doi.org/10.1002/cam4.2913

Ejemplares similares